NASH Core Curriculum: Emerging Management

Hear expert perspectives on histologic and metabolic endpoints in NASH studies and how they may inform potential targets for oral, injectable, and combination NASH treatments.
Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC
Format: Microsoft PowerPoint (.ppt)
File Size: 2.72 MB
Released: July 20, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences
Novo Nordisk Inc.

Related Content

Experts review therapeutic interventions for NAFLD/NASH, from Clinical Care Options (CCO)

Manal F. Abdelmalek, MD, MPH
Program Director
Rohit Loomba, MD, MHSc Brent Tetri, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Physician Assistants: 1.5 AAPA Category 1 CME Credits Released: December 7, 2022 Expired: December 6, 2023

Expert commentary on disease nomenclature based on underlying genetic factors, NASH heterogeneity, from Clinical Care Options (CCO)

Brent Tetri, MD Released: September 29, 2022

Expert insight on the burden and impact of HBV infection, as well as strategies to overcome barriers to vaccination, from Clinical Care Options (CCO)

Robert G. Gish, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 22, 2022 Expired: March 21, 2023

Free slides from CCO featuring data on the prevalence, assessment, and treatment landscape for NASH in people living with HIV.

Jürgen K. Rockstroh, MD Giada Sebastiani, MD Released: February 9, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings